
Physician 🇪🇨 #IM @CookCountyIMR Alumni Class of 2023/2026 - BMT/Malignant Hematology focused - FCCM UG 2016 - Tweets, my own opinion ✌🏻
Chicago, IL
Joined March 2010
- Tweets14.3K
- Following761
- Followers1K
- Likes955
Pinned Tweet
Malignant hematology, BMT and Cellular therapy! We did it! 🩸
And I survived my first week as an attending in the inpatient service! 👏
Excited for this new chapter! #AdvocateHealth bound to MKE!
1
12
373
Pierre Rodriguez retweeted
👉👉 Current NCCN guidelines for firstline Rx of CLL
- Tried to capture all essential components in one slide. Hopefully this is easier to read/understand
(For an individual patient Rx decision, several other factors including patient preference are important considerations)
Pierre Rodriguez retweeted
Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia: Are All Mutations Equal? From Molecular Classification to Treatment Selection and Measurable Residual Disease mdpi.com/4201404 #mdpicancers via @Cancers_MDPI
Pierre Rodriguez retweeted
🧐 Which will earn the first approval in relapsed AL amyloidosis: BCMA CAR-T or a bispecific? After TeclistAMY and NEXICART-2, I think we may see one soon. The next question: can either improve organ recovery enough to replace Dara-CyBorD in newly diagnosed AL? #ASH26
#mmsm #MedEd #medtwitter #myeloma #USMIRC @USMIRCNEWS @US_HMC @OpenMedKate @Larvol @oncodaily
Pierre Rodriguez retweeted
Dasatinib Dose Optimization With Weekend Drug Holiday (5 days ON , 2 days OFF ) vs 100 mg/day ,7/7 vs 50mg/day , 7/7 #leusm
Pierre Rodriguez retweeted
#ASH26 #lymsm Pembrolizumab following chemoimmunotherapy for newly diagnosed primary central nervous system lymphoma (PCNSL): An australasian leukaemia & lymphoma group open label phase II study onlineprogram.hematology.org…
Pierre Rodriguez retweeted
#Menin_inhibitors at #ASH26: a growing footprint across R/R AML, frontline combinations, MRD-directed therapy and transplant strategies.
A meeting guide to ziftomenib, revumenib, enzomenib and bleximenib:
🗓 SATURDAY, DECEMBER 12
9:30–11 am | Great Hall AD
#66, KOMET-008: ziftomenib + gilteritinib in R/R NPM1/FLT3-mutated AML. At ≥200 mg (n=41): ORR 68%, CRc 41%, CR/CRh 34%. Grade 3 differentiation syndrome 10% (n=48). Median follow-up only 4.6 months.
Abstract 66
4–5:30 pm | Great Hall AD
#388, INTERCEPT: pre-emptive revumenib for MRD relapse. MRD clearance: 45% in NPM1m (9/20 evaluable), 75% in KMT2Ar (6/8). No differentiation syndrome. Small, nonrandomized cohorts; survival benefit remains unknown.
Abstract 388
🗓 SUNDAY, DECEMBER 13
4:30–6 pm | Hall B
#661, cAMeLot-1: bleximenib phase 2 in R/R AML. CR/CRh 51.2% in KMT2Ar (n=43), 40.4% in NPM1m (n=57). Differentiation syndrome 28% and 11%, respectively. Durability remains early.
Abstract 661
#662, Beat AML: frontline azacitidine/venetoclax/revumenib in NPM1m/KMT2Ar AML, age >60 (n=82). ORR 90%, CR 68%, median OS 24.3 months. Differentiation syndrome 16%. Single-arm evidence.
Abstract 662
#663: pivotal phase 2 enzomenib in R/R KMT2Ar acute leukemia (n=56). CR/CRh threshold met; detailed response results expected at the podium.
Abstract 663
4:30–6 pm | Great Hall AD
#715: revumenib post-allo-HCT maintenance, phase 1 (n=18). No relapse, nonrelapse mortality or grade 2–4 acute GVHD at median 5.1 months. An early feasibility signal, not established relapse prevention.
Abstract 715
Poster #3418, TriNetX: menin inhibitors vs ven/HMA in R/R NPM1m AML. Mortality HR 0.28 after propensity matching. Retrospective association, not proof of comparative benefit. Time/room unverified.
Abstract 3418
🗓 MONDAY, DECEMBER 14
2:45–4:15 pm | Great Hall BC
#902, KOMET-007: ziftomenib + 7+3 + quizartinib in newly diagnosed NPM1m/FLT3-ITD AML. CRc 100% at 200/400 mg (15 evaluable); local NPM1 MRD negativity 57% of CRc. Very small cohort, short follow-up.
Abstract 902
#904, SAVE: all-oral revumenib + decitabine/cedazuridine + venetoclax in newly diagnosed unfit NPM1m/KMT2Ar AML (n=30). CRc 79%, flow-MRD negativity 91% of CRc, 1-year OS 67%. Differentiation syndrome 25%.
Abstract 904
#905, AUGMENT-101: revumenib as a bridge to HCT (n=59 transplanted in remission). MRD negativity 86% among CRc; 12-month OS 68% in KMT2Ar and 90% in NPM1m. Selected analysis of patients who reached HCT.
Abstract 905
6–8 pm | Hall F
Poster #5152: enzomenib in R/R NPM1m acute leukemia. At 300 mg BID (n=30): ORR 57%, CR/CRh 43%; differentiation syndrome 8.9% overall.
Poster 5152
Poster #5190, KOMET-001: ziftomenib in R/R NPM1wt/KMT2Ar-negative AML with MEIS1-associated lesions (n=64). CR 6%, MLFS 2%. Exploratory, hypothesis-generating. Time/room unverified.
Poster 5190
The key questions: durability, MRD depth, differentiation syndrome and the incremental benefit of adding a menin inhibitor to existing backbones.
Predominantly early-phase, single-arm data; avoid cross-trial comparisons. Abstract findings may change at presentation.
#AML #leusm #MeninInhibitors #ASH26
Pierre Rodriguez retweeted
Impact of Venetoclax Bridging on Haematopoietic Stem Cell Transplantation Outcomes in Advanced Myelodysplastic Neoplasms
astctjournal.org/article/S26…
Pierre Rodriguez retweeted
Is Allogeneic HSCT needed in Ph+ ALL #leusm
Pierre Rodriguez retweeted
1/ TP53 mutations are the worst news in higher-risk MDS. But what actually drives the prognosis — one hit or two, the size of the clone, or whether you get a transplant? Our new @ic_MDS VALIDATE @BloodCancerJnl paper, led by @tariqkewan, tackles these ?s nature.com/articles/s41408-0…
Pierre Rodriguez retweeted
#ASH26 #Weekend_Review: #TP53-mutated myeloid neoplasms
Lots to unpack across biology, prognosis, transplant & emerging therapeutic vulnerabilities. 15 abstracts that caught my attention:
1/15 O-glycosylated CD43
Identifies O-glycosylated CD43 as a potential immune-evasion pathway & therapeutic target in TP53-mut AML.
2/15 Allo-HCT in TP53-mut AML
Among pts achieving MLFS, HCT improved OS (17.7 vs 10 mo) & RFS (19.2 vs 9.2 mo), with benefit in single- & double-hit disease.
3/15 Hyperinflammation in TP53-mut AML
~10% developed an acute hyperinflammatory syndrome, often early with HMA/VEN, characterized by ↑TNF-α/sIL-2Rα but absent IFN-γ.
4/15 ATR inhibition + decitabine
Phase I study testing ATRN-119 + decitabine, exploiting potential ATR dependency from replication stress in TP53-mut AML/HR-MDS.
⭐5/15 PPM1D ≠ TP53
Our multicenter study shows #PPM1D-mut myeloid neoplasms are clinically/genomically distinct from TP53-mut disease despite convergence on DNA-damage response.
6/15 Chromosome 17 matters
Chromosome 17 abnormalities & allo-HCT emerge as independent survival predictors in TP53-mut myeloid neoplasms.
7/15 Occult multi-hit TP53
TP53-region LOH testing reclassified 32% of presumed single-hit pts as multi-hit, with outcomes resembling conventional multi-hit disease.
⭐8/15 TP53 + germline #DDX41
Somatic TP53 mutations attenuate the otherwise favorable prognosis of germline DDX41-mut myeloid neoplasms.
⭐9/15 TP53 clones after HCT
Our study tracks post-HCT relapse of monoallelic vs multi-hit TP53 disease, highlighting differences in clonal evolution after transplant.
10/15 Simplifying TP53 complexity
In >3,000 pts, multi-hit status was generally a practical proxy for biallelic TP53 inactivation, but CN-LOH deserves specific assessment.
11/15 Does TP53 function matter?
GOF, DN & LOF mutations had similar outcomes. Allelic state mattered more: biallelic disease mOS 8.3 vs 16.7 mo.
⭐12/15 Not all TP53-mut disease is the same
Our 700-pt #COMMAND_consortium study identified ~10% with targetable co-mutations & better OS (14.4 vs 6.1 mo).
With HMA/VEN: CRc 84.6% vs 53.4%; OS 17.4 vs 5.7 mo.
→ A potentially VEN-sensitive TP53 subset.
13/15 Multi-hit TP53 across MDS→AML
Its adverse prognostic effect attenuates with increasing blast burden but persists in AML, suggesting allelic state & disease phenotype interact.
14/15 Post-HCT IFN-α maintenance
Prospective phase II study evaluating IFN-α maintenance after allo-HCT for TP53-mut AML/MDS, targeting the major challenge of post-HCT relapse.
⭐15/15 Harmonizing TP53 classification
Our international collaboration addresses differences in TP53 classification & prognostication, critical for practice, trials & comparing outcomes.
Take-home: #TP53 disease is not one entity. Allelic state, LOH, cytogenetics & co-mutations matter, while HCT and emerging molecularly informed strategies continue to evolve.
#ASH26 #AML #MDS #Leusm
Pierre Rodriguez retweeted
A clone by any other name: convergence of CCUS and LR-MDS #mdsm
>>> Clinical and genomic convergence of high-risk CCUS and lower-risk myelodysplastic syndromes/neoplasms ashpublications.org/blood/ar…
New publication 📝 Results from the phase II REFINE and phase III TRANSFORM-2 trials, published in Leukemia & Lymphoma, show that SVR35 responses at Week 24 were achieved in 12% of patients with JAK inhibitor-treated myelofibrosis receiving navitoclax monotherapy (REFINE), and by 17% of patients receiving navitoclax + ruxolitinib and 7% receiving BAT (TRANSFORM-2).
Learn more about myelofibrosis: bit.ly/4snWHUc
#myelofibrosis #MPN #MPNsm #MedNews #MedEd
Pierre Rodriguez retweeted
My top @ASH_hematology #ASH26 abstracts for plasma cell disorders including myeloma and AL amyloidosis #mmsm @utswcancer
1⃣MonumenTAL-6: Tec+Tal and Tal+Pom vs EPd/PVd ➡️Phase III, RRMM after 1–4 prior lines, all exposed to anti-CD38 and lenalidomide (80% anti-CD38-refractory)
➡️n=838; median FU: 13.4 mo
➡️Tec+Tal improved PFS HR 0.11; 12-mo PFS 89% vs 30%) and OS (HR 0.38; 12-mo OS 91% vs 80%). Tal+Pom also better than control arm (PFS HR 0.27, OS HR 0.55).
🛑Grade 3/4 infections were 312% with Tec+Tal vs 25% with control (92% of patients needed IVIG), ICANS 6%, taste changes 76% and weight loss 41% (Only 6% stopped treatment for AEs)
Time limited therapy with dual targeting in pts after anti-CD38/len failure
Pierre Rodriguez retweeted
MIELOMA MÚLTIPLE: 2026
➡️Rajkumar; Am J Hematol
Elegible TCPH:
📌Inducción: Dara/Isa-VRd ➡️ TACPH
📌Mantenimiento: Lena + anti-CD38
✅Algoritmo tx de nuevo diagnóstico
💡Algoritmo tx en recaída
📍Alto riesgo IMS/IMWG y mSMART
📍Criterios dx IMWG
doi: 10.1002/ajh.70475
Pierre Rodriguez retweeted
Study in 540 ND-AML patients receiving Ven-HMA @MayoClinic : no difference in survival across the 7, 14, 21, and 28-day #venetoclax schedules; prognosis determined primarily by Mayo and ELN 2024 genetic risk and not Ven duration.
@n_gangat #Hematology
onlinelibrary.wiley.com/doi/…
Pierre Rodriguez retweeted
🧬 CAR-T abstracts I won’t miss at #ASH26!
My 10 picks across myeloma and lymphoma—from longer follow-up and earlier-line treatment to dual targeting, allogeneic platforms, and CAR-T cells generated in vivo.
The questions I’ll be watching:
🔹 Durability: How long do remissions last—and how much time can patients spend free of treatment?
🔹 Earlier treatment: Which patients benefit most from moving CAR-T forward?
🔹 Dual targeting: Can BCMA × GPRC5D or CD19/CD20 targeting reduce relapse?
🔹 Safety: Can we prevent delayed neurotoxicity while preserving disease control?
🔹 Access: Can allogeneic and in vivo approaches make CAR-T available to more patients?
Response rates attract attention. Durability, safety, patient selection, and study design determine clinical value. Small cohorts, subgroup analyses, and historical comparisons deserve careful interpretation.
These are my current picks; late-breaking abstracts may add more!
🎺 Jazz, crawfish, Hurricanes—and plenty of CAR-T discussion.
See you in New Orleans!
#ASH26 #CART #MultipleMyeloma #Lymphoma #HemeTwitter
Pierre Rodriguez retweeted
#ASH26 #ALL #leusm Nelarabine-based consolidation and maintenance in frontline high-risk adult T-cell acute lymphoblastic leukemia: Final Results of the phase 2 atriall substudy of graall-2014/T onlineprogram.hematology.org…
Pierre Rodriguez retweeted
#ASH26 #MDS #CMML Azacitidine and venetoclax in patients with higher-risk chronic myelomonocytic leukemia: Results from a prospective, multicenter phase II study with safety run-in onlineprogram.hematology.org…
Pierre Rodriguez retweeted
Hemophagocytic lymphohistiocytosis in adults: ashpublications.org/blood/ar…
Pierre Rodriguez retweeted
More to watch at #ASH26! 📅 My schedule is attached.
Thank you for flagging two important omissions from my preview:
🔹 MonumenTAL-6: Phase III Tec–Tal and Tal–Pom—PFS and OS benefits versus EPd/PVd. Major results, with safety and longer follow-up essential to interpretation.
🔹 AQUILA: Final survival analysis in the enrolled high-risk SMM population—7-year OS 87.8% vs 78.7% with daratumumab versus monitoring. Important findings to examine alongside risk definitions and treatment after progression.
Two additional highlights:
🔹 PERSEUS: Long-term MRD outcomes and MRD-guided daratumumab maintenance discontinuation.
🔹 MajesTEC-5, Arm G: Early results with ramantamig, a BCMA × GPRC5D × CD3 trispecific, plus daratumumab/lenalidomide in transplant-eligible, newly diagnosed MM, followed by ramantamig/daratumumab maintenance without planned ASCT. This is a separate cohort from the original teclistamab-based cohorts incorporating ASCT.
An increasingly crowded—and exciting—myeloma agenda in New Orleans! 🎷🦞🍹
📅 SEE THE SCHEDULE BELOW ⬇️
Our selected abstracts, dates, times, and locations—all times CST (New Orleans local time).
Dr. Fun + G
#MultipleMyeloma #mmsm #HemeTwitter
🎺🦞🍹 ASH 2026 | New Orleans: Jazz, Crawfish & Hurricanes!
But what will be the biggest breakthrough in multiple myeloma?
🔥 CAR-T vs bispecifics: Which delivers more durable disease control?
🔥 Can we safely defer ASCT?
🔥 Will bispecific maintenance improve survival?
🔥 Is MRD negativity enough, or is sustained MRD negativity what matters?
🔥 Can we finally improve outcomes in high-risk and extramedullary disease?
The real winner won’t be determined by the deepest response alone, but by durability, survival, toxicity, and time off treatment.
What is your most anticipated ASH 2026 myeloma study?
#ASH26 #MultipleMyeloma #CARTcell #bispecific #HemeTwitter
































